請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17411完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳忠仁(Chung-Jen Chen) | |
| dc.contributor.author | Chia-Ling Chang | en |
| dc.contributor.author | 張佳鈴 | zh_TW |
| dc.date.accessioned | 2021-06-08T00:11:27Z | - |
| dc.date.copyright | 2013-08-20 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-08-06 | |
| dc.identifier.citation | Hill, C., & Jones, G. (1995). Strategic management theory: an integrated approach. Boston, MA: Houghton Mifflin.
Grant, R. (2010). Contemporary strategy analysis. West Sussex, UK: John Wiley & Son Ltd. Osterwalder, A. & Pigneur, Y. (2010). Business model generation: a handbook for visionaries, game changers, and challengers. Hoboken, NJ : Wiley. Dixon, J., Lawton, G., & Machin, P. (2009). Vertical disintegration: a strategy for pharmaceutical business in 2009? Nature Reviews Drug Discovery, 8, 435. doi:10.1038/nrd2914 PhRMA. (2007). Drug discovery and development: understanding the R&D process. http://www.innovation.org/drug_discovery/objects/pdf/RD_Brochure.pdf PhRMA. (2013). Biopharmaceuticals in perspective (version 3.0). PhRMA. (2013). 2013 profile. Paul, S., Mytelka, D., Dunwiddie, C., Persinger, C., Munos, B., Lindborg, M., & Schacht, A. (2010). How to Improve R&D Productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203-214. doi:10.1038/nrd3078 林宗賢. (2009). 生技製藥產業通用鑑價模式簡介. 北美智權. http://www.naipo.com/Portals/1/web_tw/Knowledge_Center/Biotechnology/publish-3.htm Mattke, S., Klautzer, L., & Mengistu, T. (2012). Medicines as a Service – a new commercial model for big pharma in the postblockbuster world. Rand Health. Gilbert, J., Henske, P., & Singh, A. (2003). Rebuilding big pharma’s business model. In Vivo – the business & medicine report, 21, No. 10. IMS Institute for Healthcare Informatics. (2012). The global use of medicines: Outlook through 2016. EvaluatePharma. (2012). World preview 2018: Embracing the patent cliff. PriceWaterhouseCoopers. (2009). The new science of personalized medicine: Translating the promise into practice. PriceWaterhouseCoopers. (2008). Pharma 2020: Virtual R&D. Which Path Will You Take? IMS Health. (2013). The changing face of the top 10 pharmaceutical companies – the beginning of the end for innovative dominance. Accenture. (2009). Achieving high performance in pharmaceuticals through sustainable cost reduction. 許舜喨. (2013). 淺論生技新藥產業發展條例對我國生醫產業發展之影響與建議. Retrieved from 國家生技醫療產業策進會: http://www.ibmi.org.tw/client/ReportDetail.php?REFDOCTYPID=0lgfj8ve17pfj9w5&REFDOCID=0mju0zluvz4odtyg Business Monitor International. (2012). Taiwan pharmaceuticals & healthcare report, Q4 2012. 董珮真. (2008, Feb 01). 生技醫療產業商機龐大，取得國際舞台競技權. 貿易雜誌電子報. http://www.ieatpe.org.tw/magazine/200-1.htm 湯谷清. (2012). 我國明星產業競爭優勢及市場利基研究-生技及國際醫療. 台北市:行政院經濟建設委員會. 朱兆文. (2010). 生技/製藥廠商聯盟及授權標竿案例與價值分析. 台北縣汐止市: 生物技術開發中心. 商業周刊. (2012, Aug 27). 十七人小製藥公司 拚出百億市值. http://www.businessweekly.com.tw/article.php?id=47655 Burrill & Company. (2013, Feb). The Burrill Report. Pharmaengine, Inc. http://www.pharmaengine.com Merrimack Pharmaceuticals, Inc. http://www.merrimackpharma.com/solutions/pipeline/mm-398 Nanobiotix. http://www.nanobiotix.com/ Medigen Biotechnology Corp. http://www.medigen.com.tw Progen Pharmaceuticals. http://www.progen-pharma.com/ Oncolys BioPharma Inc. http://www.oncolys.com/en/index.html TaiGen Biotechnology Co., Ltd. http://www.taigenbiotech.com.tw/ | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17411 | - |
| dc.description.abstract | This study will focus on pharmaceutical / biotechnology companies with innovative new medicines. The main goal of this study is to discuss how Taiwanese biotechnology industry can become successful by conducting three different analyses. First, we will investigate whether Taiwanese biotechnology industry should adopt the full vertical integration or vertical disintegration business model by listing the key criteria for full vertical integration and vertical disintegration separately and examining whether Taiwanese companies can match each criterion. Second, we will determine the key success factors (KSFs) of No-Research-Development-Only (NRDO) biotechnology companies from the business model canvas of the NRDO business model. The third analysis will determine whether Taiwanese NRDO companies have the KSFs by inspecting the factors and resources of three example Taiwanese NRDO biotechnology companies. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T00:11:27Z (GMT). No. of bitstreams: 1 ntu-102-R00749071-1.pdf: 3123637 bytes, checksum: 3d60d8ef6ebb52d97f7754ade1a53784 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | Abstract………………………………………………………………i
Table of Contents………………………………………………………………ii List of Figures and Tables………………………………………iv Chapter 1. Introduction……………………………1 1.1 Research Motives…………………………………………………1 1.2 Research Questions………………………………………………2 Chapter 2. Literature Review………………………………………3 2.1 Vertical Integration vs. Vertical Disintegration………3 2.2 Business Model Canvas…………………………………………5 2.3 Key Success Factors……………………………………………6 Chapter 3. Methodology……………………………………………7 3.1 Measures…………………………………………………………7 3.2 Data Collection………………………………………………8 Chapter 4. Discussion…………………………………………………………9 4.1 Introduction of the Pharmaceutical Industry………9 4.2 The Traditional Business Model – Full Vertical Integration……………15 4.3 The New Business Model - Vertical Disintegration………………17 4.3.1 Causes of Disintegration…………………………………17 4.3.2 Vertical Disintegration Business Model………………22 4.4 Should Taiwanese Biotechnology Industry adopt VI or VD?…………………………24 4.5 The NRDO Business Model……………………………………31 4.6 Key Success Factors of NRDO Biotechnology Companies…………36 4.6.1 Determine Key Success Factors of NRDO from Business Model Canvas…36 4.6.2 KSF Analysis of NRDO Taiwanese Biotechnology Companies……………41 Chapter 5. Conclusion & Prospects………………………………54 5.1 Conclusion………………………………………………………54 5.2 Prospects………………………………………………………54 References………………………………………………………55 | |
| dc.language.iso | en | |
| dc.title | 台灣生技產業的NRDO商業模式 | zh_TW |
| dc.title | The NRDO Business Model in Taiwanese Biotechnology Industry | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 洪世章,林博文 | |
| dc.subject.keyword | 生技,垂直分工,NRDO, | zh_TW |
| dc.subject.keyword | biotechnology,vertical disintegration,NRDO, | en |
| dc.relation.page | 57 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2013-08-06 | |
| dc.contributor.author-college | 管理學院 | zh_TW |
| dc.contributor.author-dept | 企業管理碩士專班 | zh_TW |
| 顯示於系所單位： | 管理學院企業管理專班(Global MBA) | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 3.05 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。